![]() “There’s currently no effective pharmacologic agent for CIPN prevention, and the current strategy when patients develop CIPN is to dose-reduce their taxane therapy, which raises the concern of potentially impacting efficacy and long-term outcomes,” Accordino, director of the Hematology and Medical Oncology Fellowship Program, director of quality and patient safety in the Division of Hematology and Oncology, and associate professor of medicine at Columbia University Irving Medical Center in New York, New York, said during her presentation. ![]() In the recently reported S1714 large cohort study (NCT03939481) that included more than 1000 patients starting taxane therapy, up to 68% developed clinically meaningful CIPN.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |